Skip to content
Screener
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$69.71M-71.9%-$63.02M-35.8%-$70.69M-95.8%-$56.05M-126%-$40.56M-190%
$845K+124%$751K+106%$745K+112%$742K+117%$378K+15.2%
$13.36M+483%$3.59M+85.6%$3.71M+101%$3.31M+81.0%$2.29M+36.6%
-$66.29M-73.8%-$58.79M-21.3%-$44.54M-76.2%-$54.53M-95.5%-$38.14M-155%
$0-100%$35K-83.5%
$98K-99.8%$88.4M$88.25M+201%$56.25M+295%
$24.47M-66.5%$73.02M
$30.64M-58.1%$72.4M+47,844%$480K+162%$0$73.12M+43.4%
-$36.03M-140%$44.06M$35.12M+130%$91.14M+1,153%
-$66.29M-73.6%-$58.79M-20.9%-$44.54M-75.3%-$54.53M-95.5%-$38.18M-152%

FAQ

How much cash does MoonLake Immunotherapeutics generate?
MoonLake Immunotherapeutics (MLTX) generated -$224.2M in operating cash flow over the trailing twelve months.
What is MoonLake Immunotherapeutics's free cash flow?
After $343.0K of capital expenditures, MoonLake Immunotherapeutics's free cash flow was -$224.2M over the trailing twelve months, down 60.0% year over year.
Where does MoonLake Immunotherapeutics's cash flow data come from?
Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.